Exempting Small Biotech Firms from Medicare Drug Price Negotiation Program.
This bill creates a new exception to the Medicare drug price negotiation program, starting in 2029. It protects drugs made by small biotechnology companies that heavily invest in research and development (R&D). The goal is to ensure these smaller firms can continue innovating without immediate price controls, potentially leading to new treatments.
Key points
Small biotech companies that invest significantly in R&D are exempt from mandatory Medicare drug price negotiations.
The required R&D investment percentage varies based on how many drugs the company currently sells (30% to 70% of net revenue).
If a small company is acquired by a larger manufacturer that does not meet the R&D criteria, the drug loses its price negotiation exemption.
Expired
Citizen Poll